Retatrutide delivered up to 24.2% body weight loss in phase 2 trials at 12 mg weekly after 48 weeks (Jastreboff NEJM 2023, PMID 37366315). Start low. Titrate slow. That keeps nausea at bay. Note: retatrutide is an investigational compound that is not FDA-approved for any use (NCT04881760); the schedules below are drawn from published trial designs for educational reference only.
Reconstitution protocols for retatrutide vials
Retatrutide comes in 5 mg or 10 mg lyophilized vials. For a 5 mg vial, grab 2 ml bacteriostatic water and a 3 ml insulin syringe. Add the water. Swirl gently. No shaking. You end up with 2.5 mg per ml. A 0.5 mg dose? That's 0.2 ml, or 20 units on a U-100 syringe.
Need it stronger? Use 1 ml water for 5 mg/ml. Then 0.5 mg is 0.1 ml or 10 units. Wipe vial tops with alcohol. Stay sterile.
10 mg vials: 4 ml water gets 2.5 mg/ml. Or 2 ml for 5 mg/ml. Draw into a fresh syringe right before you inject. The retatrutide calculator handles the exact volumes.
Unlike tirzepatide in those multi-dose pens, vials let you tweak protocols however you want.
Starting dosing schedule
Week 1: 0.5 mg subQ. Abdomen, thigh, or upper arm. Rotate spots.
Week 2: 1 mg.
Week 3: 2 mg.
Week 4: 4 mg.
Nausea kicking in? Hold at 4 mg through weeks 5-8. Most people handle the climb without trouble. Weigh weekly. Log any gut issues.
This gradual ramp differs from the published trial protocols. The phase 2 obesity trial assigned fixed target doses (1, 4, 8, or 12 mg) reached via a stepped lead-in of roughly 2-4 mg, rather than a 0.5 mg start (Jastreboff NEJM 2023, PMID 37366315). A 0.5 mg starting dose appears in the phase 2 type 2 diabetes trial, not the obesity trial (Rosenstock Lancet 2023, PMID 37385280).
Maintenance dosing protocols
Tolerable? Week 9: 8 mg weekly. Week 13: 12 mg. Every 7 days, same time.
Studies showed 12 mg hit 17.5% loss at 24 weeks and 24.2% at 48. The 4 mg group? 17.1% at 48 weeks (Jastreboff NEJM 2023, PMID 37366315).
Adjust by response. No 5% loss by week 12 on 4 mg? Jump to 8. Stuck? 12 mg.
Combo ideas float around in community discussion, like low-dose retatrutide with semaglutide at 0.25 mg weekly. These stacks are anecdotal and untested in trials; note that retatrutide already contains GLP-1 receptor agonism, so adding a second GLP-1 drug like semaglutide is redundant pharmacology with no published support and a higher GI side-effect burden. Test mono first.
Run 24 weeks minimum for real fat loss data. 48 weeks maxes it out.
Injection timing and sites
Sunday mornings are convenient, ideally after 4 hours fasted to line up with your natural GLP-1 peak. SubQ: pinch the skin, go in at 45 degrees with a 31g needle.
Abdomen (2 inches from navel). Front thigh. Back of upper arm. Skip scars or bruises.
Miss by 2 days? Inject now. Over 3? Skip it. Resume normal.
Titration for tolerance
Nausea hits hardest weeks 2-4. Ginger tea 30 minutes before may help; persistent nausea or vomiting should be discussed with a licensed prescriber, who can evaluate whether an antiemetic is appropriate.
Community-reported experience suggests slow ramps cut dropouts substantially, with anecdotal figures going from around 20% to under 5%, and roughly 7% discontinuation at 12 mg versus 16% on faster tracks. These specific percentages are not from a primary source.
Diabetic? Watch blood sugar. In the phase 2 type 2 diabetes trial, retatrutide lowered HbA1c by roughly 2.0-2.2 percentage points at the 12 mg dose (Rosenstock Lancet 2023, PMID 37385280).
Storage and stability
Unreconstituted: Room temp under 25°C, dark spot. Good for 2 years.
Reconstituted: Fridge 2-8°C. Use within 28 days. No freezing. Ruins it.
Travel: Ice packs in an insulated bag, 48 hours max.
Phase 2 trial insights
338 people. 12 mg weekly: 24.2% loss versus 2.1% placebo at 48 weeks (Jastreboff NEJM 2023, PMID 37366315). Community-reported anecdotes describe waists shrinking around 18 cm.
Fasting insulin and triglyceride changes (community-reported as roughly -40% and -25%) are anecdotal here. There is no head-to-head randomized trial against tirzepatide, so any "beats tirzepatide" framing is a cross-trial comparison only; for reference, tirzepatide produced up to 20.9% weight loss in SURMOUNT-1 (Jastreboff NEJM 2022, PMID 35658024).
Liver fat dropped about 82% on a relative MRI-PDFF basis at 24 weeks (Sanyal Nat Med 2024, PMID 38858523). That is a big number for NAFLD work.
Sides: Mild GI stuff, generally easing over time. Heart rate increases of 5-10 bpm and the absence of cardiac events are community-reported observations, not established trial endpoints.
Retatrutide vs tirzepatide and semaglutide
Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. Tirzepatide: GLP-1/GIP. Semaglutide: GLP-1 only (Jastreboff NEJM 2023, PMID 37366315; Urva Lancet 2022, PMID 36354040).
Community-reported comparisons suggest it pulls ahead a few percentage points on weight loss, but there is no head-to-head trial to confirm this. The semaglutide calculator lets you compare side by side.
The idea that glucagon action preserves muscle better (anecdotally cited as 25% versus 40% lean loss on GLP-1 alone) is community-reported and not established in a primary source.
Advanced protocols for metabolic research
12 mg maintenance: at 5 mg/ml, that is 2.4 ml per dose, every 7 days.
Cycle: 12 weeks on, 4 off. The absence of tolerance out to 72 weeks is community-reported, not from a primary source.
Stacks: combining 4 mg retatrutide with 250 mcg BPC-157 daily, or 300 mcg AOD-9604 in the mornings, are anecdotal community protocols with no published evidence of benefit.
Anecdotal reports suggest cutting roughly 500 kcal daily can push total loss toward 30%, but this is community-reported, not a trial finding.
Monitoring progress
Weigh weekly, fasted, same time. DEXA at 0, 12, 24 weeks for fat versus muscle.
Bloods baseline, week 12, 24: HbA1c, lipids, ALT/AST, creatinine.
Daily hunger score 1-10. Community-reported anecdotes describe roughly a 50% drop by week 4.
Common side effects and management
Nausea: community-reported in roughly 40% early on. Hold dose. Persistent nausea or vomiting should be discussed with a licensed prescriber, who can evaluate whether an antiemetic is appropriate.
Vomiting: Under 5%. Hydrate. Electrolytes.
Fatigue weeks 1-2: 200 mg caffeine.
Itch at site: Rotate. Topical Benadryl.
Sourcing and quality checks
Buy lyophilized powder from reputable labs. Ask for 99%+ purity HPLC reports.
Vials: Lot number, expiry. Clear after recon. No floaters.
Long-term research data
Phase 3 trials are ongoing. Community-reported projections of 25-30% loss at 72 weeks for 12 mg are speculative and not yet published. Glucagon saves muscle (anecdotal).
Reassuring cardiovascular safety over 2-year extensions is likewise community-reported, not an established trial endpoint.
Practical calculator examples
80 kg subject to 12 mg:
-
Week 1: 0.5 mg = 0.2 ml (2.5 mg/ml)
-
Week 13+: 12 mg = 2.4 ml at 5 mg/ml (or 4.8 ml at 2.5 mg/ml; match the concentration you reconstituted to)
Use the retatrutide calculator for yours.
Research stacking with other peptides
2 mg retatrutide + CJC-1295/Ipamorelin 100/100 mcg nightly to support GH.
Nootropic angle: Semax 300 mcg nasal while in a deficit.
For fat loss: MOTS-c 5 mg weekly.
Diet and training integration
2 g protein per kg bodyweight. Carbs under 100 g/day.
Lift 4x weekly plus 10k steps. The glucagon component tends to leave you with more energy for it.
Troubleshooting dosing issues
No loss by week 8? Up dose. Audit calories.
Nausea won't quit? Drop 2 mg. H2 blocker.
Cloudy vial? Trash it.
Disclaimer: This info draws from clinical studies for educational purposes. Consult professionals before any use; peptides are research chemicals, not for human consumption.
References
- Jastreboff AM, Kaplan LM, Frías JP et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med, 2023. PubMed
- Rosenstock J, Frias J, Jastreboff AM et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." Lancet, 2023;402(10401):529-544. PubMed
- Urva S, Coskun T, Loh MT et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." Lancet, 2022. PubMed
- Sanyal AJ, Kaplan LM, Frias JP et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nat Med, 2024. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med, 2022. PubMed
- ClinicalTrials.gov. "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (NCT04881760)." ClinicalTrials.gov